139 related articles for article (PubMed ID: 22981641)
1. In vitro and in vivo pharmacological characterization of the main metabolites of nalfurafine hydrochloride.
Nakao K; Togashi Y; Honda T; Momen S; Umeuchi H; Sakakibara S; Tanaka T; Okano K; Mochizuki H
Eur J Pharmacol; 2012 Nov; 695(1-3):57-61. PubMed ID: 22981641
[TBL] [Abstract][Full Text] [Related]
2. Nalfurafine hydrochloride, a selective κ opioid receptor agonist, has no reinforcing effect on intravenous self-administration in rhesus monkeys.
Nakao K; Hirakata M; Miyamoto Y; Kainoh M; Wakasa Y; Yanagita T
J Pharmacol Sci; 2016 Jan; 130(1):8-14. PubMed ID: 26786553
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous scratching behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel kappa-opioid receptor agonist nalfurafine hydrochloride.
Umeuchi H; Kawashima Y; Aoki CA; Kurokawa T; Nakao K; Itoh M; Kikuchi K; Kato T; Okano K; Gershwin ME; Miyakawa H
Eur J Pharmacol; 2005 Aug; 518(2-3):133-9. PubMed ID: 16055114
[TBL] [Abstract][Full Text] [Related]
4. Nalfurafine prevents 5'-guanidinonaltrindole- and compound 48/80-induced spinal c-fos expression and attenuates 5'-guanidinonaltrindole-elicited scratching behavior in mice.
Inan S; Dun NJ; Cowan A
Neuroscience; 2009 Sep; 163(1):23-33. PubMed ID: 19524022
[TBL] [Abstract][Full Text] [Related]
5. Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats.
Lazenka ML; Moerke MJ; Townsend EA; Freeman KB; Carroll FI; Negus SS
Psychopharmacology (Berl); 2018 Jan; 235(1):203-213. PubMed ID: 29063139
[TBL] [Abstract][Full Text] [Related]
6. Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.
Schattauer SS; Kuhar JR; Song A; Chavkin C
Cell Signal; 2017 Apr; 32():59-65. PubMed ID: 28088389
[TBL] [Abstract][Full Text] [Related]
7. Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients.
Nakao K; Mochizuki H
Drugs Today (Barc); 2009 May; 45(5):323-9. PubMed ID: 19584962
[TBL] [Abstract][Full Text] [Related]
8. Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats.
Inan S; Cowan A
Pharmacol Biochem Behav; 2006 Sep; 85(1):39-43. PubMed ID: 16919318
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacological effects of nalfurafine hydrochloride, a kappa-opioid receptor agonist].
Nakao K; Hasebe K; Yoshikawa S; Ikeda K; Hirakata M; Miyamoto Y; Mochizuki H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):185-91. PubMed ID: 21226314
[TBL] [Abstract][Full Text] [Related]
10. Essential structure of the κ opioid receptor agonist nalfurafine for binding to the κ receptor.
Nagase H; Fujii H
Curr Pharm Des; 2013; 19(42):7400-14. PubMed ID: 23448474
[TBL] [Abstract][Full Text] [Related]
11. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820.
Togashi Y; Umeuchi H; Okano K; Ando N; Yoshizawa Y; Honda T; Kawamura K; Endoh T; Utsumi J; Kamei J; Tanaka T; Nagase H
Eur J Pharmacol; 2002 Jan; 435(2-3):259-64. PubMed ID: 11821035
[TBL] [Abstract][Full Text] [Related]
12. Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system.
Umeuchi H; Togashi Y; Honda T; Nakao K; Okano K; Tanaka T; Nagase H
Eur J Pharmacol; 2003 Sep; 477(1):29-35. PubMed ID: 14512095
[TBL] [Abstract][Full Text] [Related]
13. Nalfurafine suppresses pruritogen- and touch-evoked scratching behavior in models of acute and chronic itch in mice.
Akiyama T; Carstens MI; Piecha D; Steppan S; Carstens E
Acta Derm Venereol; 2015 Feb; 95(2):147-50. PubMed ID: 24890341
[TBL] [Abstract][Full Text] [Related]
14. Identification of human cytochrome P450 enzymes involved in the metabolism of a novel к-opioid receptor agonist, nalfurafine hydrochloride.
Ando A; Oshida K; Fukuyama S; Watanabe A; Hashimoto H; Miyamoto Y
Biopharm Drug Dispos; 2012 Jul; 33(5):257-64. PubMed ID: 22581509
[TBL] [Abstract][Full Text] [Related]
15. [Effect of TRK-820, a selective kappa opioid receptor agonist, on scratching behavior in an animal model of atopic dermatitis].
Nakao K; Ikeda K; Kurokawa T; Togashi Y; Umeuchi H; Honda T; Okano K; Mochizuki H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Apr; 28(2):75-83. PubMed ID: 18516986
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacological and clinical profiles of nalfurafine hydrochloride (Remitch) capsules 2.5 microg) , a new therapeutic agent for the treatment of uremic pruritus in hemodialysis patients].
Nakao K; Ando A; Hirakata M; Ando N; Takeshita K; Miyamoto Y; Mochizuki H
Nihon Yakurigaku Zasshi; 2010 May; 135(5):205-14. PubMed ID: 20467170
[No Abstract] [Full Text] [Related]
17. Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review.
Phan NQ; Lotts T; Antal A; Bernhard JD; Ständer S
Acta Derm Venereol; 2012 Sep; 92(5):555-60. PubMed ID: 22504709
[TBL] [Abstract][Full Text] [Related]
18. The effect of 17-N substituents on the activity of the opioid κ receptor in nalfurafine derivatives.
Nemoto T; Yamamoto N; Wada N; Harada Y; Tomatsu M; Ishihara M; Hirayama S; Iwai T; Fujii H; Nagase H
Bioorg Med Chem Lett; 2013 Jan; 23(1):268-72. PubMed ID: 23200250
[TBL] [Abstract][Full Text] [Related]
19. TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
Ikeda K; Yoshikawa S; Kurokawa T; Yuzawa N; Nakao K; Mochizuki H
Eur J Pharmacol; 2009 Oct; 620(1-3):42-8. PubMed ID: 19686730
[TBL] [Abstract][Full Text] [Related]
20. Nalfurafine hydrochloride for the treatment of pruritus.
Inui S
Expert Opin Pharmacother; 2012 Jul; 13(10):1507-13. PubMed ID: 22663138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
